Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual General Meeting (AGM) of Autolus Therapeutics Plc, held on June 26, 2025. The filing details the voting outcomes for nine resolutions submitted to shareholders, including the adoption of financial statements, director elections, and approval of an employee share purchase plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing references the adoption of the 2024 Annual Report and Financial Statements but does not reproduce the specific financial figures contained therein.
Material Changes and Voting Results
All nine resolutions submitted at the AGM were passed. Key voting outcomes include:
- Resolution 1 (Adoption of 2024 Accounts): Passed with 219,809,664 votes for, 97,503 against, and 477,332 abstentions.
- Resolution 2 (Directors' Remuneration Report): Passed with 216,036,710 votes for, 4,285,817 against, and 61,972 abstentions.
- Resolution 3 (Directors' Remuneration Policy): Passed with 203,397,251 votes for, 16,925,364 against, and 61,884 abstentions.
- Resolution 4 (Re-appointment of Auditors): Ernst & Young LLP was re-appointed with 220,272,345 votes for, 110,231 against, and 1,923 abstentions.
- Resolution 5 (Re-election of Dr. R Iannone): Passed with 199,042,000 votes for, 20,750,286 against, and 232,213 abstentions.
- Resolution 6 (Re-election of Dr. R Rao): Passed with 219,956,853 votes for, 194,729 against, and 232,197 abstentions.
- Resolution 7 (Employee Share Purchase Plan): Approved with 219,651,874 votes for, 706,780 against, and 25,845 abstentions. The plan authorizes the issuance of 3,000,000 shares.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies beyond the standard governance matters addressed in the resolutions. The text notes that the Directors' remuneration policy took effect immediately after the conclusion of the AGM.
Investor Verification Checklist
- Verify the full text of the 2024 Annual Report and Financial Statements referenced in Resolution 1 for detailed financial performance.
- Review the definitive proxy statement filed on June 02, 2025, for detailed descriptions of the resolutions and director biographies.
- Confirm the specific terms of the newly approved Employee Share Purchase Plan with Sharesave Sub-Plan, including eligibility and pricing mechanisms.
- Monitor the implementation of the new Directors' remuneration policy effective post-AGM.